Drugmaker AstraZeneca shifts more production to US amid Trump tariffs

<p>UK and rest of Europe risk losing out to US and China unless they ramp up spending on new medicines, says CEO Pascal Soriot</p><ul><li><a href="https://www.theguardian.com/business/live/2025/apr/29/hsbc-trade-war-bad-debts-trump-automotive-tariffs-stock-markets-business-live-news">Business live – latest updates</a></li></ul><p>AstraZeneca said it was shifting the production of some medicines sold in the United States from Europe to the US, to counter the impact of Donald Trump’s <a href="https://www.theguardian.com/business/internationaltrade">trade tariffs</a>.</p><p>Speaking as the company reported higher sales and profits for the first quarter, the FTSE 100 pharma company reiterated that the UK, and the <a href="https://www.theguardian.com/business/2025/apr/09/eu-drug-firms-warn-of-exodus-to-us-as-trump-threatens-import-tariffs">rest of Europe, risked losing out</a> to the US and China unless they ramped up spending on new medicines. Pascal Soriot, AstraZeneca’s chief executive, warned that “well-paid” advanced manufacturing and research jobs could move to the US in the long run.</p> <a href="https://www.theguardian.com/business/2025/apr/29/astrazeneca-production-us-trump-tariffs-uk-europe-pascal-soriot">Continue reading...</a>